Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

57.70 +0.58 (+1.01%)

Streaming Delayed Price Updated: 3:59 PM EST, Feb 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >

Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

September 20, 2023

EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END

Via FinancialNewsMedia

Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030

September 08, 2023

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END

Via FinancialNewsMedia

FDA Accepts Application for Genentech’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition

September 06, 2023

From Genentech

Via Business Wire

Genentech’s Alecensa Delivers Unprecedented Phase III Results for People With ALK-Positive Early-Stage Lung Cancer

September 01, 2023

From Genentech

Via Business Wire

Genentech Provides Update on Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer

August 23, 2023

From Genentech

Via Business Wire

New Clinical and Real-World Data for Genentech’s Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss

July 20, 2023

From Genentech

Via Business Wire

Nvidia Invested $50 million into This AI Drug Discovery Biotech

July 17, 2023

Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from

Via MarketBeat

Topics Artificial Intelligence

Positive Phase III Results for Genentech’s Ocrevus (ocrelizumab) Twice a Year, 10-Minute Subcutaneous Injection in Patients With Multiple Sclerosis

July 13, 2023

From Genentech

Via Business Wire

Four-Year Follow-Up Data for Genentech’s Evrysdi Show Continued Increase in Number of Children With a Severe Form of Spinal Muscular Atrophy (SMA) Able to Sit, Stand and Walk

June 30, 2023

From Genentech

Via Business Wire

Agilent Technologies Stock: Ready to Rise off the Floor

June 21, 2023

Agilent Technologies Inc. (NYSE: A) stock is underperforming the market, trading down (19%) year-to-date. Agilent is a leading global provider.

Via MarketBeat

FDA Approves Genentech’s Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

June 15, 2023

From Genentech

Via Business Wire

New Data Show Genentech’s Subcutaneously Administered Crovalimab Achieved Disease Control and Was Well-Tolerated in People With Paroxysmal Nocturnal Hemoglobinuria (PNH)

June 09, 2023

From Genentech

Via Business Wire

Genentech’s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions in People With Relapsing Forms of Multiple Sclerosis

May 17, 2023

From Genentech

Via Business Wire

Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy

May 16, 2023

Sarepta Therapeutics soars 31% as FDA committee supports gene therapy for Duchenne muscular dystrophy. Analysts have a "moderate buy" rating on the stock.

Via MarketBeat

FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)

May 09, 2023

From Genentech

Via Business Wire

Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales

May 05, 2023

Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo.

Via MarketBeat

New Vabysmo Data Suggest Greater Retinal Drying Versus Aflibercept in Wet Age-Related Macular Degeneration and Diabetic Macular Edema

April 25, 2023

From Genentech

Via Business Wire

Genentech Announces Industry-Leading Brain Health Research Collaborations and Latest Data Across Neuroscience Medicines at AAN 2023 Annual Meeting

April 24, 2023

From Genentech

Via Business Wire

FDA Approves Genentech’s Polivy in Combination With R-CHP for People With Certain Types of Previously Untreated Diffuse Large B-cell Lymphoma

April 19, 2023

From Genentech

Via Business Wire

Genentech’s Tecentriq Plus Avastin Reduced the Risk of Cancer Returning in People With Certain Types of Adjuvant Liver Cancer in a Phase III Study

April 16, 2023

From Genentech

Via Business Wire

Genentech Data Highlights Strength of Ophthalmology Portfolio and Commitment to Advancing Eye Care at ARVO 2023

April 13, 2023

From Genentech

Via Business Wire

New Four-Year Data for Genentech’s Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA)

March 20, 2023

From Genentech

Via Business Wire

Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode

March 15, 2023

FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 15, 2023 – USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for...

Via FinancialNewsMedia

FDA Advisory Committee Votes in Favor of the Clinical Benefit of Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma

March 09, 2023

From Genentech

Via Business Wire

New Phase III Data Show Genentech’s Vabysmo Rapidly Improved Vision and Reduced Retinal Fluid in People With Retinal Vein Occlusion (RVO)

February 10, 2023

From Genentech

Via Business Wire

Genentech Announces Positive Data From Global Phase III Program for Crovalimab in PNH, a Rare, Life-Threatening Blood Condition

February 07, 2023

From Genentech

Via Business Wire

Genentech’s Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial

January 19, 2023

From Genentech

Via Business Wire

FDA Grants Priority Review to Genentech’s Bispecific Antibody Glofitamab for People With Relapsed or Refractory Large B-Cell Lymphoma

January 06, 2023

From Genentech

Via Business Wire

Big Health Care Stocks to Watch in the New Year

December 29, 2022

Here are three health care stocks to watch as the New Year begins. Two have a moderate Buy rating while one is a Hold, for now.

Via MarketBeat

FDA Approves Genentech’s Lunsumio, a First-in-Class Bispecific Antibody, to Treat People With Relapsed or Refractory Follicular Lymphoma

December 22, 2022

From Genentech

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

Press Releases about Roche Holding AG Basel American Depositary Shares

Starting at $3.75/week.

Subscribe Today